According to CDE information, Haihe Pharmaceutical’s PI3Kα inhibitor CYH33 tablets, lyvgen Biopharma’s CD137 activating antibody LVGN6051 monoclonal antibody injection, and Lynk Pharmaceutical’s LNK01001 capsule have been approved for clinical use.
正在翻译中..